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Abstract
Noninvasive positive ventilation has undergone a remarkable
evolution over the past decades and is assuming an important role
in the management of both acute and chronic respiratory failure.
Long-term ventilatory support should be considered a standard of
care to treat selected patients following an intensive care unit
(ICU) stay. In this setting, appropriate use of noninvasive ventilation
can be expected to improve patient outcomes, reduce ICU
admission, enhance patient comfort, and increase the efficiency of
health care resource utilization. Current literature indicates that
noninvasive ventilation improves and stabilizes the clinical course
of many patients with chronic ventilatory failure. Noninvasive
ventilation also permits long-term mechanical ventilation to be an
acceptable option for patients who otherwise would not have been
treated if tracheostomy were the only alternative. Nevertheless,
these results appear to be better in patients with neuromuscular/-
parietal disorders than in chronic obstructive pulmonary disease.
This clinical review will address the use of noninvasive ventilation
(not including continuous positive airway pressure) mainly in
diseases responsible for chronic hypoventilation (that is, restrictive
disorders, including neuromuscular disease and lung disease) and
incidentally in others such as obstructive sleep apnea or problems
of central drive.
Introduction
After the successful use of tracheostomy and intermittent
positive pressure ventilation (IPPV) in the 1950s to treat
acute bulbar poliomyelitis [1], some patients were discharged
at home with long-term mechanical ventilation via tracheo-
stomy (invasive) or mouth piece (noninvasive) [2,3]. However,
it was only in the 1980s after the introduction of noninvasive
positive pressure ventilation (NIPPV) through facial interfaces
in the intensive care unit (ICU) that long-term NIPPV was
considered as a standard of care to treat selected patients
following an ICU stay. NIPPV is now a predominant technique
for long-term home ventilation [4]. It is also well recognized
that NIPPV allows patients treated for acute failure from
chronic respiratory insufficiency to be discharged from
hospital and also prevents readmissions [5,6]. These
beneficial effects have been reported for both chronic
obstructive pulmonary disease (COPD) and neuromuscular/
parietal disorders [6]. Depending on the underlying diseases
and the severity, IPPV is either continuously mandatory to
avoid death in cases of complete or quasi-complete paralysis
or is used nightly, producing enough improvement to allow
free time during the daytime for spontaneous breathing. This
clinical review will address the use of NIPPV (not including
continuous positive airway pressure (CPAP)) in the different
diseases for which it is currently proposed.
Methods of NIPPV and their uses
Interfaces
The need to select an appropriate and properly fitted inter-
face cannot be overemphasized due to its impact on the
quality of ventilation [7]. The aim is to reach a compromise
between different objectives: to minimize leaks, improve
comfort and implement the mask easily. A wide variety of
different factory-made masks of different designs, shapes,
sizes and materials is now available. It is usually possible to
find a mask that suits most individuals. Because of this, the
initial practice of custom made interfaces for different
individuals is now seldom needed, even if it remains probably
the best interface [7,8]. There are currently four different
types of interfaces: nasal masks, which are used
predominantly [8,9]; facial masks covering the nose and the
mouth; nasal pillows; and mouthpieces [9], which are now
essentially indicated in the case of daytime ventilation [10].
Mouthpieces may afford an excellent interface to provide
adjunct daytime ventilation in neuromuscular patients who are
unable to maintain acceptable diurnal arterial blood gases
without frequent intermittent periods of assistance. The
mouthpiece is positioned close to the patient’s mouth where
it is intermittently captured to take a few assisted breaths
from the ventilator and subsequently released. An advantage
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of this is that the face is free from face-attached interfaces.
Patients needing assistance night and day may use a
combination of interfaces.
Ventilators and modes for NIPPV
Ventilators use one of two basic methods: volume-preset and
pressure-preset [9]. With volume-preset, the ventilator always
delivers the tidal volume that is set by the clinician, regardless
of the patient’s pulmonary system mechanics (compliance,
resistance and active inspiration). However, leaks at the skin-
mask interface, or through the mouth when using a nasal
mask, reduce the volume received by the patient. Conversely,
with pressure-preset, changes in pulmonary mechanics
directly influence the flow and the delivered tidal volume
(lower or higher) since the ventilator delivers the set pressure
throughout inspiration. In this case, leaks augment the flow
and tend to maintain the tidal volume [11]. More recently, a
third method has been proposed for both ICU and home
ventilation. This is called pressure-preset/volume-targeted
and aims to guarantee delivery of a tidal volume with the
comfort of the pressure-preset method. At the present time,
clinical evaluation of this third method remains poorly
documented [12]. It is important to understand that NIPPV is
dominated by both rapidly varying non-intentional leaks and
the geometry and the resistance of the upper airway [13].
Obviously, leaks and airway resistance partly interact. In the
face of these continuous changes the respective advantages
and drawbacks of volume- and pressure-preset methods,
which are opposite, make it difficult to predict their effects.
The way inspiration begins and ends is initiated either by the
ventilator or in response to a patient effort to do so, allowing
one to define the main modes of ventilation: control, assist-
control, and assist or spontaneous (assist or spontaneous
possible only with pressure-preset).
Most home ventilators function according to only one of the
methods, volume-preset or pressure-preset, but modern ones
may deliver inspiration by both methods. Besides the classic
circuitry, including two valves (on the inspiratory and
expiratory limbs) alternately closing and opening, bilevel
positive airway pressure (BPAP) ventilators are simpler and,
therefore, lend themselves to home mechanical ventilation
[14]. Inspiratory and expiratory pressures are alternatively
established in a single circuit incorporating an intentional,
calibrated leak located close to the patient or even on the
mask. The theoretical disadvantage with such a circuit is the
risk of variable CO2 rebreathing. However, concern about the
risk of CO2 rebreathing has not been definitively documented
[15], although the trend is to consider it as negligible
provided positive expiratory pressure is applied in order to
eliminate CO2 through the intentional leak (at least 2 to
4 cmH2O) [16]. Depending on the ventilator, all the different
modes and refined settings, and even closed-loop modes
usually applied in the ICU, are more or less available. Some
ventilators may analyze ventilation in an on-going manner and
keep the data in internal memory for further assessment. The
general objective is to provide many possible capabilities in
order to have enough tools to adapt and optimize patient-
machine synchronization. While conceptually attractive,
sufficient studies have not been performed to document or
refute the advantages of such complexity in the context of
noninvasive home ventilation.
Choice of the ventilator and mode
Many clinicians currently prefer a pressure-preset ventilator in
assist mode as the first choice with a view to offering the best
synchronization [4]. In fact, in the studies comparing volume
and pressure-preset ventilators, no clear differences in the
correction of hypoventilation in short-term studies [17,18]
and long-term outcomes [19,20] have been shown. This is
understandable since leaks and resistance changes during
NIPPV alternate very quickly and when the pressure target is
well achieved, the volume target is not, and vice versa.
However, it is important to remain flexible by trying alternative
approaches if problems occur with one or the other type of
ventilator.
Additionally, even if new generations of BPAP ventilators tend
to contain batteries, it should be noted that these batteries
most often provide autonomy of only short duration. This
would limit security and mobility of neuromuscular patients
with hypoventilation and then shift the preference to the
volume ventilator.
Criteria to consider when deciding on the
implementation of NIPPV
Signs and symptoms of hypoventilation
The presence of clinical symptoms and/or physiological
markers of hypoventilation are useful in identifying clinical
severity as it relates to therapeutic decision-making with
regard to initiation of nocturnal NIPPV. In the course of a
typically progressing disease, two successive steps occur
more or less rapidly: nocturnal hypoventilation that is
reversible during waking hours associated with none or a few
clinical symptoms; and nocturnal and daytime hypoventilation
associated with clinical symptoms that show a low respiratory
reserve and should be considered an unstable state with
increased susceptibility to life-threatening acute ventilatory
failure that may be triggered by what may otherwise be trivial
additional factors [21,22]. A sleep study continuously
recording CO2 (end-tidal (EtCO2) or transcutaneous
(TcCO2)) and/or pulse oximetry (SpO2) is required to
document nocturnal hypoventilation, which may occur
throughout all sleep stages but in some cases exclusively
during rapid eye movement sleep. Daytime hypoventilation is
defined by abnormally elevated partial pressure of arterial
carbon dioxide (PaCO2), a high serum bicarbonate level and
a relatively normal pH with associated reduction of the partial
pressure of arterial oxygen (PaO2). Chronic daytime hypo-
ventilation is an important indicator invariably associated with
sleep-related hypoventilation. Thus, in the presence of diurnal
hypoventilation, the reason for overnight recording is only toPage 3 of 9
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rule out obstructive or central apnea. Clinical symptoms
indicating consequences of hypoventilation (Table 1) must be
carefully evaluated since, even when modest, they are
important for the appreciation of disease severity and
prognosis and in the indication of NIPPV. Pulmonary function
tests help define and quantify the ventilatory-respiratory
disease but have low predictive values for chronic sleep-
related hypoventilation in individual patients except in those
with neuromuscular disease. Indeed, in Duchenne muscular
dystrophy, hypoventilation appears only during rapid eye
movement sleep, all night, or during the daytime when supine
inspiratory vital capacity is <40%, <25% and <12%,
respectively [21]. Similarly, a peak cough flow <160 l/min,
related to expiratory muscle deficit, means an increased risk
of accumulation of secretions that may worsen hypo-
ventilation and trigger acute failure [23]. It is crucial to note
that isolated reduced PaO2 does not require mechanical
ventilation but only supplemental oxygen because it does not
indicate hypoventilation but only a mismatching of ventilation
and perfusion.
Diseases that may potentially be treated with NIPPV
The principal diseases that may be addressed using NIPPV
therapy are shown in Table 2. Except for those due to
respiratory control or upper airway abnormalities, all may
become severe enough to cause alveolar hypoventilation
during sleep and daytime and eventually may impair the
quality of life and threaten life. In neuromuscular disorders, it
is important to consider the progressiveness according to
each type of disease and the individual concerned.
Survival with NIPPV in different diseases
NIPPV efficacy in terms of survival compared to control
treatment is important information required in order to
adequately discuss NIPPV. Besides a few randomized control
trials [24-27], this information comes from retrospective
series compared to the usual prognosis [20,28-31]. In order
to extend the analysis, it is also possible to take into account
results obtained with either negative pressure ventilation [32]
or tracheostomy [2]. These are informative enough and
generally accepted by the medical community even if
conclusions derived from them are refutable in terms of
evidence-based medicine. In neuromuscular disease, NIPPV
always increases survival. Approximate median increased
survival times depend on the age of the patient when starting
NIPPV and the comorbidities present (including extended
paralysis): very long (>20 years) in the sequelae of
poliomyelitis; long (10 years) in spinal muscular atrophy type
2 and 3, Duchenne muscular dystrophy, and acid maltase
deficiency; short (4 years) in myotonic dystrophy; and very
short (1 year) in amyotrophic lateral sclerosis (ALS). In cases
of chest-wall abnormalities, NIPPV also prolongs life:
15 years in kyphosis and 7 years in the sequelae of
tuberculosis. No data support a positive effect on survival in
lung diseases: in COPD patients randomized trials are
negative [25,26,32], and data are too scarce in cystic fibrosis
or for bronchiectasis patients. However, we must note that
the negative results in the trials in COPD may be related to
insufficient ventilation due to a too low driving pressure.
Circumstances and indications for NIPPV
In clinical practice, NIPPV is initiated either electively or in the
context of acute ventilatory failure initially treated invasively
with translaryngeal intubation or noninvasively with facial
interfaces [33]. In the latter circumstances, the long-term
necessity for NIPPV should be reevaluated after weeks or
months during follow-up since the indications for NIPPV may
change as the clinical conditions improve or not. In cases of
chronic and stable awake hypoventilation, the main criteria for
predicting the need for NIPPV are advanced severity with
clinical symptoms of hypoventilation plus a balance of several
other issues, including: the main primary process explaining
the hypoventilation - mechanical or lung deficit; whether the
natural rate of progression has been a few years or dozens of
years; the clinical severity at the time of decision making;
actual symptoms and history of acute-subacute failure in the
previous months; and the patient’s willingness, including the
family and social environment, to undertake this therapy.
Indications for NIPPV are outlined in Table 3. NIPPV is
strongly indicated in patients with chest wall and neuro-
muscular disorders in the presence of clinical symptoms
attributable to diurnal hypoventilation [34-37]. There are no
validated values above which NIPPV is definitely indicated;
however, many clinicians consider treatment in scoliosis and
sequelae of tuberculosis with awake PaCO2 >50 to 55 mmHg
and a PaO2 <60 mmHg, and in neuromuscular disease with a
PaCO2 around 45 to 50 mmHg and a PaO2 <70 mmHg. In
cases with clear clinical symptoms, less severe values may be
considered as an indication to start NIPPV [35]. Conversely,
in COPD and probably in other lung diseases, diurnal hypo-
ventilation does not support the unequivocal utility of NIPPV
[38,39]. Nevertheless, this question remains open since the
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Table 1
Clinical features frequently associated with alveolar
hypoventilation
Shortness of breath during activities of daily living in the absence of
paralysis
Orthopnea in patients with disordered diaphragmatic dysfunction
Poor sleep quality: insomnia, nightmares and frequent arousals
Nocturnal or early morning headaches
Daytime fatigue, drowsiness and sleepiness, loss of energy
Decrease in intellectual performance
Loss of appetite and weight loss
Appearance of recurrent complications: respiratory infections
Clinical signs of cor pulmonaleclinical trials are underpowered and secondary parameters,
such as some components of the quality of life or hospitali-
zation days, may have improved. Some observational series
suggest better results [40,41]. Presently, we may admit
NIPPV as an option in COPD patients with symptoms of
hypoventilation contributing to recurrence of acute-subacute
failure, provided that long-term oxygen and drug therapy have
already been optimally adjusted. During early stages with only
isolated nocturnal hypoventilation, NIPPV is not mandatory
but could be optional in kyphoscoliosis and neuromuscular
diseases [42]. In the latter, when worsening is both inevitable
and rapid (for example, ALS), NIPPV is valuable at an early
stage provided that this is an acceptable therapeutic option
for the patient.
NIPPV use in some other diseases may also deserve
consideration even if clinical experience remains inconclusive.
Obesity hypoventilation syndrome is dominated by morbid
obesity impeding ventilation, frequent obstructive apnea and
more or less reversible decreased reactivity of the respiratory
centers [43]. In acute-subacute as in chronic situations,
NIPPV has been shown to reverse hypoventilation [44,45].
However, considering the high prevalence of obstructive
apnea, CPAP is a simpler and efficient treatment. In addition,
CPAP reduces the resistance of the pharynx, which leads to
a light reduction of the work of breathing. This may be
another reason for the reversal of the hypoventilation.
Cheyne-Stokes breathing with central and obstructive apnea
in the context of severe cardiac insufficiency has been shown
to negatively influence the clinical situation and survival [46].
Conventional  NIPPV or a new modality, such as adaptive
servo-ventilation, has been shown to alleviate apnea and
improve cardiac function [47,48]. Nevertheless, no conclusion
about the utility of nocturnal NIPPV in terms of survival and
main outcomes is available. In addition, a recent large study
comparing oxygen and CPAP, which also alleviates apnea and
improves cardiac function, does not prove the clinical
superiority of CPAP in terms of survival [49]. Pure obstructive
sleep apneas in the context of obstructive sleep apnea could
be suppressed with NIPPV. Some authors have proposed
NIPPV as a second-line treatment in the case of CPAP failure.
However, this is not supported with enough conclusive study
to be recommended [50]. Ondine’s curse, in children, is
characterized by the lack of metabolic response of the
respiratory centers during sleep and is responsible for severe
nocturnal hypoventilation. The usual treatment is tracheostomy
and nocturnal ventilation. Some clinical experience suggests
that, after years, tracheostomy might be converted in some
cases to nocturnal NIPPV. Obviously, such options must
remain in the hands of specialized teams [51].
Management of NIPPV
Initiation and settings for nocturnal ventilation
The main goal of NIPPV, which in the best circumstances is
used solely during the night, is to improve arterial blood
gases up to nearly normal values without discomfort and
sleep disruption. However, day time mechanical ventilation in
chronic respiratory insufficiency is as good as night time
ventilation. The reduction of hypercapnia depends more on
the duration of the ventilation than on whether the patient is
asleep or awake [52]. The objective when there is residual
muscle ability to breathe is to provide enough improvement to
allow comfortable time off the ventilator. Even if there is no
absolute recommendation, it is good general practice to
proceed in three steps. The first step consists of selecting
and adjusting the ventilator settings while the patient is
awake, insuring physiological adequacy and patient comfort
for at least one or two hours. One study, done on awake
cystic fibrosis patients, found that clinical observation is as
efficient as the use of physiological measurements, including
esophageal pressure, in setting the ventilator parameters
[53]. Another in patients with COPD and neuromuscular
disease has shown that using physiological measurements
does not improve ventilation during the day but improves
ventilation and sleep quality during the night [54,55].
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Table 2
Main diseases that can benefit from NIPPV classified
according to the cause and progressiveness of the respiratory
impairment
Parietal disorders (PFT abnormal; ↓ VC, ↓ FEV1, → FEV1/VC, ↓ RV, 
↓ TLC)
Chest wall
Kyphoscoliosis No worsening
Sequelae of tuberculosis Slow worsening
Obesity hypoventilation  Depends on obesity
syndrome
Neuromuscular disorders
Spinal muscular atrophy No worsening
Acid maltase deficit Slow worsening (>15 years)
Duchenne muscular dystrophy Intermediate worsening 
(5 to 15 years)
Myotonic myopathy Intermediate worsening 
(5 to 15 years)
Amyotrophic lateral sclerosis Rapid worsening 
(0 to 3 years)
Lung diseases (PFT abnormal; → or ↓ VC, ↓ FEV1, ↓ FEV1/VC, 
↑ RV, ↑ TLC)
COPD Continuous worsening
Bronchiectasis, cystic fibrosis Continuous worsening
Predominant ventilatory control abnormalities (PFT normal)
Ondine’s curse Improvement?
Cheyne-Stokes breathing Depends on heart failure
Upper airway abnormalities (PFT normal)
Obstructive sleep apnea No worsening
Symbols indicate actual compared to theoretical values: ↓, decrease;
↑, increase; →, normal. COPD, chronic obstructive pulmonary disease;
FEV1, forced expiratory volume in 1 second; NIPPV, noninvasive
positive pressure ventilation; PFT, pulmonary function test; RV, residual
volume; TLC, total lung capacity; VC, vital capacity.In the second step, the clinician should judge adequacy when
the patient is napping and/or during nocturnal use. To
complete this step, different options according to the
resources available in each center could be used. Arterial
blood gas (ABG) measurements would seem ideal; however,
one or a few samples during the night do not represent the
rapid changes observed during several continuous hours of
sleep, and the invasiveness of sampling has led most
clinicians to noninvasively monitor different parameters.
Ideally, a complete polysomnogram recording SpO2 and
TcCO2 or EtCO2, airflow, tidal volume, airway pressure, rib
cage and abdomen excursion, and sleep staging permits a
complete assessment [56]. When resources are not available
to perform these detailed recordings, fewer measurements
during overnight recordings remain informative. However, the
minimal requirement is to record SpO2 overnight in room air,
assessing whether the normalization of SpO2 accompanies a
normalization, or at least an improvement, of PaCO2. In
addition, data related to patient tolerance, comfort, sleep
quality and well-being should be obtained.
The third step is carried out after several nights of NIPPV and
consists of looking for a reduction in PaCO2  and
augmentation of PaO2, without dyspnea, during the day when
free from ventilation to confirm that the settings are adequate.
This also gives information about the necessity or not to add
daylight hours of NIPPV (at first during napping and more
when necessary). If the results are not satisfactory, alterations
must be made to the settings and possibly the mask and the
ventilator, and the effects of these checked again. In most
cases, a few days are necessary to achieve success.
If one uses assist pressure-preset ventilation, 10 cmH2O of
inspiratory pressure support is a suggested starting point. If
necessary, the pressure level is progressively increased to
achieve evidence of improvement. Pressure support higher
than 20 cmH2O is rarely necessary. Nevertheless, one
observational series reports good results in COPD patients
ventilated with higher (28 cmH2O) pressure [41]. In COPD,
the addition of an expiratory positive pressure (positive end-
expiratory pressure (PEEP) or expiratory positive airway
pressure (EPAP)), also necessary to decrease the rebreathing
with BPAP ventilators, should conceptually improve patient
triggering when intrinsic PEEP exists [57]; however, there is
no long-term study proving its clinical usefulness. Depending
on the ventilator capabilities and observations made of how
the patient and ventilator do together, more subtle settings
concerning triggers, initial flow, and inspiratory time limit could
be tried. A backup frequency set close to the spontaneous
frequency of the patient during sleep is a reasonable
substitute to avoid central apnea induced by transitory but
repeated hyperventilation exceeding the apnea threshold [58].
When employing a volume-preset ventilator, the initial
suggested settings may be established by adjusting the
frequency of ventilator-delivered breaths so that it approxi-
mates the patient’s spontaneous breathing frequency during
sleep, an inspiratory time/total breathing cycle time between
0.33 and 0.50 and a relatively high tidal volume of around 10
to 15 ml/kg to insure sufficient tidal volume in case of leaks [59].
Supplemental oxygen should be added into the ventilator
circuit in those patients requiring oxygen while awake due to
lung parenchyma diseases (for example, COPD, cystic
fibrosis, bronchiectasis). In the absence of parenchymal
disease it is only after trying to optimize all technical
parameters that residual desaturation may justify additional
oxygen bled into the ventilator circuit during sleep [60].
Continuous NIPPV
In neuromuscular diseases (and to a lesser degree in end-
stage lung diseases), ventilator dependency may be total
when starting NIPPV or may progressively increase following
the gradual worsening of the disease. In cases of continuous
Available online http://ccforum.com/content/11/2/210
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Table 3
Typical indications for nocturnal NIPPV according to disease process and severity
Symptoms and  Symptoms and  No/limited symptoms  Usual daily duration 
Disease night/day CO2 ↑ only night CO2 ↑ but night/day CO2 ↑ of NIPPV
Scoliosis Yes Yes Perhaps <12 hours
Tuberculosis Yes Yes Perhaps <12 hours
Neuromuscular stable or slow Yes Perhaps Perhaps 18-24 hours
Neuromuscular intermediate Yes Perhaps Perhaps 18-24 hours
Neuromuscular rapid Yes Yes Yes 24 hours
COPD Perhaps No No 12 hours
Bronchiectasis/cystic fibrosis Perhaps No No 18-24 hours
Obesity hypoventilation Perhaps Perhaps No <12 hours
↑, Increase; COPD, chronic obstructive pulmonary disease ; NIPPV, noninvasive positive pressure ventilation.need for ventilation, NIPPV could be used provided that
interfaces are alternated night and day and assisted coughing
is made available [37,61]. Only a very well trained team that
is completely informed and conscious of the constraints and
dangers involved may take such an approach in patients.
Such application has been reported by different teams in
stable neuromuscular patients, such as those with a sequelae
of poliomyelitis, high-level spinal cord injury or Duchenne
muscular dystrophy [10,62]. Alternatively, a tracheostomy
may be performed to facilitate ventilatory assistance and
secretion removal.
There is no clear answer as to whether, and beyond what
duration, a totally ventilator-dependent patient is better or
more safely ventilated by tracheostomy or NIPPV [35,63,64].
This debate will probably continue and, in the end, the
decision to indicate NIPPV or to convert to tracheostomy is
highly dependent on the philosophy and capabilities of the
clinical team as well as that of the patient and their family
environmental preferences. It is essential that discussion of
such issues be started as early as possible in the patient’s
course, well before the imperative arises.
Swallowing dysfunction, which is responsible for frequent
and massive aspirations and pneumonia and is observed
during the course of ALS (frequent occurrence and is due to
bulbar origin) or Duchenne muscular dystrophy (occurs
seldomly and is due to muscle weakness), is an imperative
indication for tracheostomy to prolong survival, although
tracheostomy causes major difficulties for communication and
reduces opportunities for personal interactions, leading to a
locked-in state [64]. In this context, NIPPV, which may be
easily stopped, could be the most reasonable option in cases
of rapidly devastating diseases like ALS, and can be
considered by both the patient and medical team as a
limitation of care or a palliative approach [65]. This was
confirmed in a study in which NIPPV in ALS patients with
bulbar symptoms do not increase survival longer than
controls [27].
Follow-up
Clinical follow-up and daytime ABG measurements (or their
surrogates) should be conducted regularly (twice per year,
for example). When possible, recordings during sleep when
on NIPPV, identical to those taken when initiating NIPPV, are
useful. At any time when there are unsatisfactory results, such
as recurrence of clinical symptoms or hypoventilation on
ABG, inadequate NIPPV must be suspected and objective
evaluation during sleep must be undertaken. At the very least,
overnight oximetry must be done. When NIPPV is determined
to be suboptimal, a change in ventilator modality or setting
and a review of the mask fitting may be indicated. Increasing
the total duration of NIPPV use per day should also be
considered, particularly when the underlying disease has
progressed. Masks have to be regularly checked and
changed or adapted as needed.
Management of complications
Air leaks during NIPPV
To some degree, leaks are present when using nasal NIPPV
during sleep in all patients. The major potential adverse
effects of such leaks are reduced efficiency of ventilation and
sleep fragmentation [66,67]. A variety of measures, more or
less efficacious, have been suggested to address proble-
matic leaks. These include preventing neck flexion, reclining
in a semi-recumbent position, discouraging the mouth from
opening by use of a chin strap [67] or a cervical collar,
switching to pressure-preset mode [59], decreasing the peak
inspiratory pressure, increasing the delivered volume [11],
optimizing the interface [7,8], and possibly switching to nasal
pillows or a full face mask [68]. The effectiveness of these
measures must be confirmed during sleep recordings.
Nasal dryness, congestion, and rhinitis
With reference to the CPAP literature, the side effects of
nasal dryness, congestion, and rhinitis are related to a defect
of humidification promoted by air leaks [69]. For patients with
nasal and mouth dryness, a cold passover or a heated
humidifier (the latter is more effective) can be used [70].
Heat/moisture exchangers are not well adapted in cases of
leaks since the ‘dry’ flow from the ventilator is higher than the
‘dampened’ flow returning from the patient. In a large series, a
minority of patients needed humidifiers [9].
Aerophagia
Aerophagia, or swallowing air, is frequently reported by
patients but is rarely intolerable [71]. Minor clinical signs are
eructation, flatulence and abdominal discomfort. Aerophagia
is usually dependent on the level of inspiratory pressure and
is more commonly seen when using volume and/or mouth-
piece ventilation and in the care of patients with neuro-
muscular disease. The incidence decreases if the peak
inspiratory pressure is kept below 25 cmH20 pressure.
NIPPV effects (other than survival) and
related mechanisms
During ventilatory assistance
As expected, when under NIPPV, ventilation and gas
exchange are improved in all types of disease [19,72,73],
even if significant episodes of transient hypoventilation
related to mouth leaks may appear [66,67]. Duration of sleep
is augmented without clear changes in its quality [65,74].
Respiratory muscles are normally put at rest but there are
many exceptions due to air leaks and patient-ventilator
asynchrony [75].
After ventilation
When spontaneous ventilation exists, and in the absence of
major lung disease, gas exchange remains improved after
NIPPV is stopped. This may persist for hours and even days
before reappearance of hypoventilation [76]. The
improvement reported in many studies is important in chest-
wall and neuromuscular diseases but inconsistent in COPD
Critical Care    Vol 11 No 2 Robert and Argaud
Page 6 of 9
(page number not for citation purposes)[72,77]. Certainly, NIPPV can account for improvements in
clinical symptoms such as general well-being, appetite,
exercise capability, headaches, ankle edema, and resurgence
of acute failure, as well as decreasing hospitalization,
increasing quality of life [78] and improving survival.
Three main explanations for these improvements after NIPPV
have been proposed: improved respiratory muscle strength,
resetting of the chemoreceptors, and decrease of the
ventilatory load. The first hypothesis suggests that ventilatory
assistance rests the respiratory muscles, thereby reversing
fatigue. Indeed, inspiratory force has been found to be
significantly augmented in a few studies [30,79]. The second
hypothesis suggests that, in response to chronic hypercapnia
and hypoxia, the chemoreceptors commanding the respira-
tory centers change their set point, which perpetuates hypo-
ventilation rather than attempting to generate non-sustainable
ventilatory muscle efforts [80]. The resumption of better
ventilation during NIPPV would reset the centers to more
normal values. The third hypothesis suggests that an improve-
ment in respiratory chest-wall and/or lung compliance, under
the effects of positive pressure ventilation, would reduce the
ventilatory load and increase the efficiency of the muscles. In
the studies done on scoliosis, vital capacity significantly
increased [30,79]; however, in other diseases, including
neuromuscular patients, the vital capacity remained
unchanged. In one study, chest-wall and lung compliance did
not change even though there was a nonsignificant trend
towards an increase [81]. Furthermore, periodic hyper-
insufflation using higher inspiratory pressures for a few
minutes in scoliosis [82] and ALS [83] patients revealed an
increase in compliance. It seems probable that, even if the
mechanisms that explain the efficacy of NIPPV are imperfectly
understood, several factors, even if not individually significant,
change and interact together to improve alveolar ventilation.
The minimum mandatory duration of assistance is not clearly
known. However, a relationship between a decrease in
PaCO2 and the pressure to ventilate has been found [79].
Finally, one study reports a significant decrease in pulmonary
arterial hypertension, which obviously favors clinical
improvement [84].
In COPD patients, the absence of clinical results compared
to those obtained for scoliosis and neuromuscular disease,
even if resetting of the respiratory centers has been shown
[85], could be explained by the relatively low impairment of
respiratory muscles and the importance of the lesions of the
lung itself and its progressiveness.
Conclusions
Chronic ventilatory support using NIPPV improves and
stabilizes the clinical course of many patients with chronic
ventilatory failure. The results appear to be good in patients
with restrictive disorders and poor in COPD. Among the
neuromuscular disorders results are better in the slowly
progressing ones. The benefit of NIPPV is reflected by
improvements in survival, blood gas composition and clinical
stability, which help avoid the risk of acute failure and/or ICU
admissions. Due to its relative simplicity and its non-invasive
nature, NIPPV permits long-term mechanical ventilation to be
an acceptable option for patients who otherwise would not
have been treated if tracheostomy were the only alternative. In
this way, nocturnal NIPPV represents a huge advance.
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